PHARMACIA NICOTINE NASAL SPRAY REQUIRES DISTRIBUTION RECORDS
• By The Pink Sheet
PHARMACIA NICOTINE NASAL SPRAY REQUIRES DISTRIBUTION RECORDS be kept to help prevent abuse of the smoking cessation product if it is approved for marketing, FDA's Drug Abuse Advisory Committee recommended Aug. 1. The committee also recommended a limit be imposed on the number of refill prescriptions patients could obtain without reassessment by the prescriber. The panel recommended against requiring triplicate prescriptions or secured storage areas for the product. Pharmacia's NDA for the nicotine nasal spray as an aid to smoking cessation was filed in July 1993.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.
Darko has become the first director-general of the AMA, an organization set up to transform access to quality-assured medicines across Africa and foster a more predictable, efficient regulatory environment for innovation.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.